3/24/2022

speaker
Operator
Conference Call Moderator

Good morning and welcome to Avela Biosciences conference call to discuss its fourth quarter and full year 2021 business highlights. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to Kendra Sweeney of Avela. Please proceed.

speaker
Kendra Sweeney
Investor Relations, Avela Biosciences

This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.avelobio.com under the Investors tab. Today on our call, Simba Gill, Chief Executive Officer, Mark Bodmer, President of R&D and Chief Scientific Officer, and Jonathan Zung, Chief Development Officer, will review our recent business highlights. Before we begin, I would like to remind everyone that statements made during this conference call that do not relate to matters of historical fact, including statements about our objectives and anticipated clinical milestones, the impact of any of our product candidates, and the timing and results of any clinical studies should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual results could differ materially from those indicated by the forward-looking statements due to the impact of many factors. Participants are directed to the risk factors set forth in Avella's annual report on Form 10-K for the fiscal year ended December 31, 2021, and the company's other filings with the Securities and Exchange Commission. Any forward-looking statements made today speak only to Avello's operations as of today. Avello disclaims any duty to provide updates to its forward-looking statements, even if subsequent events cause the company's views to change. It is now my pleasure to pass the call to Simba.

speaker
Simba Gill
Chief Executive Officer

Thank you, Kendra. Good morning, everyone, and thank you for joining us to review our progress during the fourth quarter. We are fortunate to face the headwinds of the current financial market from a position of strength, clinically and scientifically. Our goal on this call is simple, to provide you with the evidence that Avello has an exceptional opportunity to create value with a high probability of success. This bold statement from a mid clinical stage company working in new biology on a new modality of medicine is objectively rooted in both clinical and preclinical data. However much we do not like our current share price, it represents an exceptional opportunity for investors in both the short and the long term. We started working on syntax medicines five years ago with a radically innovative proposal that there is a connection between the small intestine and the rest of the immune system that would enable orally delivered gut-restricted drugs to safely modulate immunity and inflammation throughout the body. Preclinical and clinical results have been remarkable. We have observed coordinated downregulation of multiple inflammatory pathways driving inflammation resolution in both lab animals and in humans. And we now have a good understanding of the immunological mechanism that allows this to happen. The top line EDP 1815 phase two psoriasis clinical data that we reported last September demonstrated that a syntax medicine can have a therapeutic effect with safety and tolerability comparable to placebo. And as we heard from both Dr. Stroba as well as Dr. Daniel Rowling at a KOL event, Avello's Phase II clinical data supports the potential use of EDP-1815 in almost all patients, including, importantly, the mild and moderate population, which represents over 85% of the 55 million patients with psoriasis worldwide who are generally not treated with biologics or oral small molecules. The primary unmet need in psoriasis is for this segment of patients. We can't emphasize enough the importance of the clinical data. The trial addressed the central question, can targeting syntax be the basis for a completely new type and class of medicine? The answer is yes. Since September, we have reported two further data sets from the phase two trial. The first clinical data set was the reduced production of multiple inflammatory cytokines from blood immune cells of patients receiving EDP 1815. These reductions were statistically significant. Similar reductions were seen in skin biopsies for IL-12, IL-17, and IL-23, all validated cytokines in the skin pathology of psoriasis. This is human mechanistic evidence for inflammation resolution, similar to what we have long observed in animal models. The second clinical data set was the 24-week follow-up data from psoriasis patients in Part B of the Phase II trial after they stopped taking EDP-1815. Many patients had persistent and deepening responses with no flares or rebound of psoriasis consistent with what we now know about the cellular mechanism of action of EDP1815 from preclinical studies. We are delighted to announce data from this Phase II trial has been selected for a coveted late-breaking oral presentation this Saturday at 10.10 a.m. Eastern Time at the 2022 meeting of the American Association of Dermatology. significant external recognition for the potential of syntax medicines. The broad set of data are fundamental evidence for a new area of biology which we can harness to create effective, safe, oral, affordable medicines to treat all chronic inflammatory diseases. In a moment, I'm going to hand over to Mark Bodmer to talk about the scientific discoveries that underpin these clinical successes. Before doing that, we wanted to announce today further exciting positive data from the clinical trial examining a faster release capsule. As you know, we have been investigating the potential to consistently improve the release characteristics of our syntax medicines. The aim is to see consistent faster release higher up in the small intestine. Imaging results from the next phase of the study demonstrated that the improved release capsules of EDP-1815 are able to deliver drug faster and then higher up in the small intestine 88% of the time. Mark will explain these results in the context of preclinical evidence that clearly predicts the potential for increased efficacy with this release profile. Putting all of this together, we will focus on this faster release capsule as we advance our programs into later stage development. The faster release capsule gives us confidence that we are likely to see even greater efficacy than we have seen to date, both in terms of proportion of responders and in depth of response. Mark and Jonathan will now talk about our science and the clinical development plans, and then we'll wrap up with a view of what to expect next. Mark, over to you. Thanks, Simba.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-